Effektivnost' i bezopasnost' vtorichnoy profilaktiki ishemicheskogo insul'ta antitrombotsitarnymi preparatami i peroral'nymi antikoagulyantami


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Ischemic stroke (IS) is a common serious disease characterized by high mortality and permanent disability. Cardioembolism is one of the common pathogenetic subtypes of IS. The most effective way to prevent the development of this subtype of IS includes the use of indirect anticoagulants, such as warfarin. Its effectiveness has been repeatedly confirmed by clinical studies. The drug is characterized by reliable anticoagulant effect with acceptable cost to most patients. The apparent advantage of warfarin is the ability to laboratory control of anticoagulant effect. It is important to emphasize the absence of the drug nephrotoxicity and hepatotoxicity. The application of warfarin for the prevention of IS is discussed.

全文:

受限制的访问

参考

  1. Гусев Е.И., Скворцова В.И., Стаховская Л.В. Эпидемиология инсульта в России. Журнал неврол. и психиатр. им. С.С. Корсакова. Инсульт. 2003;8:4-9.
  2. Mozaffarian D., Benjamin J., Go A., et al. Heart Disease and Stroke Statistics-2015 Update. A Report From the American Heart Association. Circulation. 2015;131:e1-e293.
  3. Lovett J., Coull A., Rothwell P. Early risk of recurrence by subtype of ischemic stroke in population-based incidence studies. Neurology. 2004;62:569-73.
  4. Жетишев Р.Р, Камчатнов П.Р., Михайлова Н.А., Иващенко А.Р. Асимптомный инсульт. Журнал неврол. и психиатр. им. С.С. Корсакова. 2013;3(2):53-6.
  5. Vermeer S.E, Hollander M., Van Dijk E., Hofman A., Koudstaal P.J, Breteler M.M. Silent brain infarcts and white matter lesions increase stroke risk in the general population: the Rotterdam Scan Study. Stroke. 2003;34:1126-29.
  6. Фрис Я.Е., Камчатнов П.Р., Шелякина Л.А. Информированность населения о факторах риска сосудистых заболеваний головного мозга и клинических проявлений инсульта. Журнал неврол. и психиатр. им. С.С.Корсакова. 2010;9(2):3-12.
  7. Хакимова С. Варфарин и его наследство: новая эра антикоагулянтов или эра новых антикоагулянтов? http://ap.nursingtoday.ru/ news/726/.
  8. Sacco R., Adams R., Albers G., et al. Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack: The American Academy of Neurology affirms the value of this guideline. A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association Council on Stroke. Circulation. 2006; 113:e409-49.
  9. Niinuma Y., Saito T., Takahashi M., Tsukada C., Ito M., Hirasawa N., Hiratsuka M. Functional characterization of 32 CYP2C9 allelic variants. Pharmacogenomics J. 2014;14(2):107-14.
  10. Кукес В.Г. Метаболизм лекарственных средств: клинико-фармакологические аспекты. М., 2004. C. 18-27, 40-7.
  11. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J. Am. Colled. Surg. 2002; 194:267-73.
  12. Rost S., Fregin A., Ivaskevicius V., Conzelmann E., Hörtnagel K., Pelz H.J., Lappegard K., Seifried E., Scharrer I., Tuddenham E.G., Müller C.R., Strom T.M., Oldenburg J. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004; 427:537-41.
  13. Gage B., Waterman A., Shannon W., Boechler M., Rich M.W., Radford M.J. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285:2864-70.
  14. Hippisley-Cox J., Coupland C., Brindle P. Derivation and validation of QStroke score for predicting risk of ischemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. Br. Med. J. 2013;346:f2573 doi: 10.1136/bmj.f2573.
  15. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch. Intern. Med. 1994;154:1449-57.
  16. Lane A., Lip G. Use of the CHA2DS2-VASc and HAS-BLED Scores to Aid Decision Making for Thromboprophylaxis in Nonvalvular Atrial Fibrillation. Circulation. 2012;126:860-65.
  17. Chimowitz M., Lynn M., Howlett-Smith H., Stern B.J., Hertzberg V.S., Frankel M.R., Levine S.R.,
  18. Steinberg B., Kim S., Piccini J., Fonarow G.C., Lopes R.D., Thomas L., Ezekowitz M.D., Ansell J., Kowey P., Singer D.E., Gersh B., Mahaffey K.W., Hylek E., Go A.S., Chang P., Peterson E.D. Use and Associated Risks of Concomitant Aspirin Therapy with Oral Anticoagulation in Patients with Atrial Fibrillation: Insights from the ORBIT-AF Registry. Circulation. 2013;128(7):721-28.
  19. Castro T., Heineck I. Interventions to improve anticoagulation with warfarin. Ther. Drug Monitor. 2012;34(2):209-16.
  20. Uno T., Sugimoto K., Sugawara K., Tateishi T. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole. Ther. Drug Monitor. 2008;30(3):276-81.
  21. Holbrook A., Pereira J., Labiris R., McDonald H., Douketis J.D., Crowther M., Wells P.S. Systematic overview of warfarin and its drug and food interactions. Arch. Intern. Med. 2005;165(10):1095-106.
  22. Donzе J., Clair C., Hug B., Rodondi N., Waeber G., Cornuz J., Aujesky D. Risk of falls and major bleeds in patients on oral anticoagulation therapy. Am. J. Med. 2012;125(8):773-78.
  23. De Schryver E., van Gijn J., Kappelle L., Koudstaal P.J., Algra A. Non-adherence to aspirin or oral anticoagulants in secondary prevention after ischemic stroke. J. Neurol. 2005;252(11): 1316-21.
  24. Armstrong J., Gronseth G., Anderson D., Biller J, Cucchiara B., Dafer R., Goldstein L.B., Schneck M., Messе S.R. Summary of evidence-based guideline: Periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;80:2065-69.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2015
##common.cookie##